Blurbs

J.P. Morgan Remains a Buy on Pacific Biosciences (PACB)

J.P. Morgan analyst Julia Qin maintained a Buy rating on Pacific Biosciences (PACBResearch Report) yesterday and set a price target of $13.00. The company’s shares closed yesterday at $10.63.

Qin covers the Healthcare sector, focusing on stocks such as Seer, Invitae, and Singular Genomics Systems. According to TipRanks, Qin has an average return of 2.4% and a 50.00% success rate on recommended stocks.

In addition to J.P. Morgan, Pacific Biosciences also received a Buy from Canaccord Genuity’s Kyle Mikson CFA in a report issued on November 16. However, on the same day, Piper Sandler maintained a Hold rating on Pacific Biosciences (NASDAQ: PACB).

See Insiders’ Hot Stocks on TipRanks >>

PACB market cap is currently $2.4B and has a P/E ratio of -7.93.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PACB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Read More on PACB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More